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Abstract
Background: We formulated mianserin suppositories for the treatment of delirium and evaluated their pharmacokinetics
by measuring plasma drug concentrations in dogs and healthy human volunteers.
Methods: Mianserin suppositories were prepared by a melting technique using Tetramide® tablets and Witepsol H-15
as the suppository base. Pharmacokinetics of this 30-mg mianserin preparation were evaluated in three beagle dogs
and three healthy adult males, in line with ethics committee approval. Plasma mianserin levels were determined using
gas chromatography–mass spectrometry.
Results: In dogs, the maximum plasma mianserin concentration (Cmax) was 1.3 ± 0.4 ng/mL, the time to Cmax (tmax)
was 5.5 ± 4.3 h, and the area under the plasma concentration-time curve from 0 to 24 h (AUC0-24) was 18.9 ±
1.9 h・ng/mL. In humans, the Cmax was 14.6 ± 6.3 ng/mL, the tmax was 8 h, and the AUC0-24 was 266 ± 103 h・ng/mL.
Conclusions: The current study characterized the pharmacokinetics of mianserin suppositories in dogs and humans. As
compared to oral administration, the suppositories produced a lower Cmax and a delayed tmax, although AUC0-24 values
were comparable. It will be necessary to identify an appropriate dose that produces an adequate plasma mianserin
concentration for effective and safe clinical use.
Trial registration: UMIN000013853.
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Background
Typical antipsychotics such as haloperidol, atypical anti-
psychotics (risperidone, perospirone, quetiapine, and
olanzapine), and tetracyclic antidepressants (mianserin
and trazodone) have been used to treat delirium [1–3].
At present, haloperidol injection is the only treatment
option available to patients who have difficulties with
oral administration. Although haloperidol has been used
widely to treat delirium, it can cause extrapyramidal dis-
order. Therefore, there is a need to develop alternative
drugs for parenteral and/or non-tube administration in
the general ward and at home.
Mianserin is a tetracyclic antidepressant with a weak
affinity for cholinergic receptors; its antidepressant effect
is considered to derive mainly from blockade of pre-
synaptic alpha2-adrenoceptors, with a consequent in-
crease in noradrenergic neurotransmission [4, 5]. There
are several theories relating to the pathogenesis of delirium,
including an alteration in serotonin neurotransmission [6].
The mechanism of mianserin-induced improvement of de-
lirium remains unclear, but may be attributable to mianser-
in’s selective antagonism of 5-HT2 receptors [7].
Unlike other antipsychotics used to treat delirium,
mianserin is unlikely to cause extrapyramidal effects.
There is no high-quality clinical research evidence, such
as a randomized controlled trial, for the efficacy of mian-
serin in the treatment of delirium. However, some non-
randomized trials have reported the efficacy of mianserin
for treating delirium. Sixty-two consecutive in-patients
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with a mean age of 80.7 years who were diagnosed with
delirium were orally administered 10–90 mg mianserin/
day (one administration in the evening) and assessed
weekly using the Delirium Rating Scale over a 4-week
study period. This study reported that mianserin was ef-
fective, particularly for the treatment of behavioral dis-
turbances (85.5 % improvement rate) [8]. A separate
open-label study demonstrated that 67 % of 46 patients
(mean age: 63.0 years) who received 10–60 mg mian-
serin/day showed marked improvements [9]; these re-
sults were similar to those observed in a positive control
group administered 2–6 mg haloperidol/day in which
improvements were observed in 71 % of 17 patients.
We established a formulation for mianserin supposi-
tories, prepared using a melting method and mianserin
hydrochloride tablets: Tetramide® and Witepsol H-15
(Vosco®) [10]. H-15 was selected as the suppository base
because the average drug release rate from mianserin-
H15 suppositories is higher than that from mianserin-
W35 or mianserin-S55 [10].
Rectal administration partially avoids the first pass ef-
fect, resulting in higher blood levels of drugs that are
subject to extensive first pass metabolism following oral
administration. A study in six healthy male subjects indi-
cated a first-pass fraction of approximately 32 % follow-
ing oral administration of mianserin hydrochloride [11].
Therefore, rectal administration of mianserin may result
in a higher plasma drug concentration than that produced
by oral administration, which may induce over-sedation.
Therefore, prior to clinical application, we needed to
characterize the pharmacokinetic profile of mianserin after
rectal administration using a suppository.
The present study characterizes the pharmacokinetics
of a mianserin suppository in an experimental animal
prior to conducting a human study. Rats, rabbits, and
dogs are frequently used for pharmacokinetic studies of
suppositories. We selected dogs to test these human-sized
suppositories. Secondly, we characterized the pharmaco-
kinetics of mianserin after administering the rectal sup-
pository in healthy adult volunteers. The results of this
study provide information about the appropriate dose for
future studies of the efficacy of mianserin suppositories in




Mianserin hydrochloride 10-mg tablets (Tetramide®)
were purchased from MSD K.K. (Tokyo, Japan). Witep-
sol H-15 (Vosco® H-15), a hard fat suppository base, was
purchased from Maruishi Pharmaceutical Co., Ltd.
(Osaka, Japan). Mianserin hydrochloride standard was
purchased from Sigma-Aldrich, Inc. (MO, USA).
Mianserin-d3 dihydrochloride (1,2,3,4,10,14b-hexahydro-
2-(methyl-d3)-dibenzo[c,f]pyrazino[1,2-a]azepine hydro-
chloride) was purchased as an internal standard from
Santa Cruz Biotechnology, Inc. (Texas, USA). Methanol
(high-performance liquid chromatography [HPLC] grade),
n-hexane (HPLC grade), and isoamyl alcohol were pur-
chased from WAKO (Osaka, Japan). All other chemicals
were analytical grade. Pooled human plasma was pur-
chased from Cosmo Bio Co., Ltd. (Tokyo, Japan).
Suppository preparation
In this study, we prepared two types of suppositories in
a clean room (class 10,000) at the Pharmaceutical De-
partment, Yokohama City University Medical Center.
Mianserin tablets were ground to a powder using a pes-
tle and mortar and sifted using a 50-μm sieve. One gram
of the mianserin tablet powder contained 100 mg mian-
serin hydrochloride. Witepsol H-15 base was melted at
40 °C and then the powder was added and mixed by stir-
ring. Mianserin 30 mg suppositories were composed of a
1.1 g base and 0.3 g mianserin tablet powder. The mol-
ten mixture (1.4 mL) was aspirated into plastic supposi-
tory molds (1.35 mL; Kanae Co., Ltd., Osaka, Japan)
using a glass injection syringe and allowed to solidify at
room temperature. The suppositories were wrapped in
aluminum foil to protect them from light and stored at
4 °C until use.
Pharmacokinetic study in dogs
Six male beagle dogs aged 19–20 months were fasted
from 6 p.m. on the day before mianserin administration
to 8 h after administration. The dogs were randomized
into two groups with three dogs in each group; one
group received oral mianserin tablets and the other
group received a rectal mianserin suppository.
Blood samples (5 mL) were collected before and 0.5, 1,
2, 4, 8, and 24 h after drug administration, transferred to
tubes containing heparin sodium, inverted, and stored in
an ice-cold box. Plasma was subsequently prepared and
stored at −20 °C until it was analyzed.
The animal experimental procedures were conducted
in accordance with the Regulations of the Ethics Review
Committee for Animal Experimentation, and the Rules
for the Approval of Animal Experimentation of KAC
Co., Ltd. (Kyoto, Japan). The experimental protocol was
approved by the animal experiment ethics committee of
Showa University.
Pharmacokinetic study in humans
This open-label, single-dose study was registered as a
University Hospital Medical Information Network Clin-
ical Trials Registry Clinical Trial (ID: UMIN000013853).
The study was conducted according to the ethical princi-
ples of the Declaration of Helsinki and the Japanese
Ministry of Health, Labour and Welfare. The study
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protocol was approved by the ethical committees of
Showa University Karasuyama Hospital (receipt no. B-
2013-021). Written informed consent was obtained from
the participants, who were healthy male volunteers aged
between 20 and 45 that were considered competent to
provide consent, able to adhere to the rules of this study,
and able to report their own symptoms; all subjects were
judged eligible by the investigator after several medical
check-ups. Subjects were excluded from study participa-
tion if their medical history was inappropriate (for ex-
ample, a history of drug abuse, alcoholism, any kind of
heart, liver, kidney, lung, eye, blood diseases or digestive
system disorders, etc.) or if they ingested medicines dur-
ing the study. Further exclusion criteria were as follows:
smoker; any drug allergy; regular use of excessive alcohol
with no abstention for the study period; participation in
any clinical trial within the last 3 months; and subjects
deemed inadequate for enrollment by the investigators.
The target sample size was three. This was the minimum
number of subjects and was chosen because this study
was the first pharmacokinetic analysis of rectal mian-
serin administration. The subjects fasted for 14 h prior
to drug administration until 3 h after administration.
Suppositories (30 mg) were stored at 4 °C and brought
to room temperature 30 min prior to administration to
each subject by a nurse at 9 a.m. Blood samples (4 mL)
were collected in heparinized tubes before and 0.5, 1, 2,
4, 8, and 24 h after mianserin administration. The sam-
ples were immediately centrifuged at 3,000 rpm for
10 min at 4 °C. Plasma was transferred to another two
sample tubes and immediately frozen at −30 °C.
Outcomes
Primary outcomes were pharmacokinetic parameters
(maximum plasma mianserin concentration [Cmax],
time of Cmax [tmax], and area under the plasma
concentration-time curve from 0 to 24 h [AUC0-24]).
Secondary outcomes were self-assessment of sedation
and safety profiles.
Self-assessment of sedation
Self-assessment of sedation was conducted prior to
mianserin administration and 1, 2, 4, 8, and 24 h after
administration; this was carried out 5 min before blood
sampling to avoid altering the assessment. A visual ana-
log scale, based on the Bond & Lader scale [12] trans-
lated into Japanese [13], was used to evaluate subjective
sedation. The questionnaire included 16 question pairs.
Between the question pair (for example, “alert” at the
left-hand side and “drowsy” at the right-hand side), there
was a 100 mm-long ungraded horizontal line. Each sub-
ject used a vertical line (|) to indicate their own estimate
of sedation. The distance along the 100-mm line from
the more sedate state to the subject’s mark was used for
analysis. The average value from nine of 16 items was
calculated as the sedation score at each time-point. The
subjects were not told the items that would be measured
or the direction of the measurement. New question-
naires were distributed to subjects at every time point so
that they did not have access to their previous estimates.
Safety
Safety was evaluated using the following approaches: 1)
medical interview and examination prior to administra-
tion and 4 and 24 h after administration; 2) vital signs
(pulse and blood pressure in the sitting position after
5 min rest) and the axillary temperature before adminis-
tration and at 4 and 24 h after administration; and 3)
survey of subjective symptoms before administration
and at 1, 2, 4, 8, and 24 h after administration.
Plasma mianserin determination
The samples were transferred to the Division of Clinical
Pharmacy, Department of Pharmacotherapeutics, Showa
University School of Pharmacy, where the plasma mian-
serin concentration was determined using gas chroma-
tography–mass spectrometry (GC-MS) [14].
Primary stock solutions of mianserin and mianserin-d3
dihydrochloride were prepared in methanol at a concen-
tration of 1 mg/mL and further dilutions to the desired
concentrations were made using methanol. These solu-
tions were stored protected from light at approximately
−20 °C.
After the internal standard (mianserin-d3; 50 μL of
0.2 ng/μL) was added to the 500-μL sample, it was
mixed with 500 μL 2 M NaOH and vortexed [15]. The
mixture was diluted with 5 mL hexane-isoamyl alcohol
(99:1) and shaken for 30 min. After centrifuging the
sample at 2000 g for 10 min, the upper layer was trans-
ferred to a new glass tube and evaporated under nitro-
gen at 40 °C. The evaporated extract was dissolved in
100 μL methanol.
A calibration curve was prepared using dog or human
plasma (450 μL) containing mianserin (50 μL) to achieve
concentrations of 15, 7.5, 3.75, 1.875, 0.938, 0.469, and
0.234 ng/mL. These values were plotted on the x-axis,
while the y axis was used to plot the area ratio (area of
the mianserin peak/area of the internal standard).
A GCMS-QP2010 Ultra system (Shimadzu, Kyoto,
Japan) equipped with a Rtx-5MS column (30 m × 0.25
mmφ × 0.25 μm; Shimadzu GLC, Tokyo, Japan) was
used. The initial column temperature was set at 90 °C
for 1 min and then ramped at 50 °C/min to 180 °C,
where it was held for 10 min; thereafter, the
temperature was ramped again at 10 °C/min to 300 °C
and held for 5 min. Helium with a constant flow of
1.52 mL/min and a pressure of 108.6 kPa was used as
the carrier gas. A sample volume of 1 μL was injected
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in a splitless mode, with a 1-min sampling time. MS
employed an ion source temperature of 230 °C and an
electron voltage of 70 eV. Selective ion monitoring
mode was used with m/z = 264 for mianserin and m/z
= 267 for mianserin-d3.
Mianserin and internal standard peaks were not de-
tected in a blank sample (plasma) or a zero concentra-
tion sample (blank sample with internal standard). At a
signal/noise ratio = 3, the limit of detection was 0.2 ng/
mL. The limit of quantitation was 0.234 ng/mL. The cor-
relation coefficient of the calibration line was r = 0.999,
and the mean accuracy was 7 %.
Data analysis
The Cmax and tmax were obtained by inspection of the
plasma concentration-time curve. The trapezoidal
method was used to calculate AUC0-24. The AUC from
time zero to infinity (AUC∞) was calculated as the sum
of AUC0–24 plus the ratio of the last measurable concen-
tration to the elimination rate constant (ke). Because
data from the elimination phase were insufficient to esti-
mate ke, we used the reported ke value (0.039, calculated
by dividing 0.693 by 18 h, which is half the time re-
ported in the Tetramide® insert). According to the prin-
ciples of pharmacokinetics, ke values do not depend on
the route of administration.
To estimate the pharmacokinetic parameters of
mianserin after administration by suppository, the 1-
compartment model with first-order absorption equa-
tion (1) was fitted using a nonlinear least-squares
regression analysis, which was conducted using the
MULTI program [16]:
C tð Þ ¼ D:ka:F=Vd= ka‐keð Þ
 exp ‐ke:tð Þ‐ exp ‐ka:tð Þf g ð1Þ
where C represents the plasma mianserin levels, t repre-
sents time, D represents the dose, ka is the absorption
rate constant, F is the bioavailability, Vd is the volume of
distribution, and ke is the elimination rate constant. For
these calculations, we fixed ke according to the reported
value (0.039).
We used the obtained parameters and equation (1) to
simulate the time-dependent changes in mianserin levels
following mianserin suppository administration. The tar-
get plasma mianserin levels were 20–40 ng/mL and 60–
80 ng/mL. The former is the steady state level achieved
by daily oral administration of 30 mg Tetramide® tablets
to healthy adults. The latter was set in reference to pre-
vious studies of plasma mianserin levels 11–13 h after
once-a-day oral mianserin administration and the effect
of mianserin on delirium [9, 17].
Results
Dog pharmacokinetics
The plasma concentration-time profiles after administra-
tion of 30 mg mianserin by rectal suppository and oral
tablet are shown in Fig. 1. After oral administration, the
plasma mianserin level reached Cmax at 30 min and then
rapidly decreased. By 24 h after oral administration, the
plasma mianserin level was below the lower limitation of
quantitation. Plasma concentrations after rectal adminis-
tration were lower than those observed after oral adminis-
tration and these remained at 1 ng/mL for 8 h. By 24 h
after rectal administration, the plasma mianserin concen-
tration was 0.42 ± 0.07 ng/mL, higher than that observed
after oral administration. The dog pharmacokinetic pa-
rameters are summarized in Table 1. Rectal administration
resulted in a delayed tmax, a lower Cmax, and an AUC0–24
value that was 70 % of that observed following oral
administration.
Human pharmacokinetics
Three healthy male Japanese subjects with a mean age of
24.7 years (range: 23–26 years), a mean height (± stand-
ard deviation [SD]) of 177.3 ± 5.9 cm, and a mean weight
of 72.1 ± 7.1 kg completed this study. Their mean (± SD)
plasma mianserin concentration-time profiles after ad-
ministration of a rectal suppository are shown in Fig. 2,
indicating that absorption of mianserin commenced im-
mediately after rectal administration of the suppository
and then slowly increased over time. Consistent with the
dog data, the tmax was delayed, the Cmax was lower, and
the AUC0–24 was 79 % of that estimated from the avail-
able human oral data (Table 2). The estimated AUC∞
value after administration of a rectal suppository was
124 % of the AUC∞ value reported in the package insert
for oral administration (Table 2).
The estimated values of ka and Vd/F were 0.146 ±
0.052 1/h (mean ± SD, n = 3) and 1395 ± 497 L, respect-
ively. The fitted curve and observed mianserin levels are
shown in Fig. 2. Using the reported ke value and param-
eters estimated in this study, we simulated the mianserin
time profiles after daily administration for 4 days (Fig. 3).
The schedule of 30 mg daily achieved a level of 17–
25 ng/mL. A twice-daily dosage of 30 mg was necessary
to obtain plasma mianserin levels of 40–45 ng/mL. A
twice-daily dosage of 60 mg was predicted to result in
plasma mianserin levels of 80–90 ng/mL.
Sedation scores (mean ± SD, n = 3) at 30 min, 1, 2, 4,
8, and 24 h after drug administration were 53.7 ±
3.8 mm, 56.7 ± 7.4 mm, 57.3 ± 7.0 mm, 59 ± 6.6 mm, 55
± 5.6 mm, and 48.7 ± 4.2 mm, respectively; these did not
differ significantly from those recorded prior to drug ad-
ministration (51 ± 3.6 mm; repeated-measures ANOVA).
One of the study subjects reported adverse events asso-
ciated with administration of mianserin. He complained of
Nawata et al. Journal of Pharmaceutical Health Care and Sciences  (2016) 2:12 Page 4 of 7
an unpleasant mood, followed by a transiently disturbed
consciousness during lunch (4 h after administration) and
supper (8 h after administration). His pulse and blood
pressure decreased and he recovered after bed rest. A
medical examination 24 h after administration found that
all of his vital signs were normal and he did not report
any subjective symptoms.
Discussion
To characterize mianserin suppository pharmacokinetics,
we conducted this pilot study of a single rectal administra-
tion of a mianserin (30 mg) suppository in dogs and
healthy adult volunteers. The study showed that blood
mianserin concentrations increased more slowly following
rectal administration than after oral administration.
This is the first study, to our knowledge, to provide
pharmacokinetic data relating to mianserin in dogs. The
values of tmax, Cmax, and AUC0-24 following oral admin-
istration to dogs were 25, 21, and 8 % of the correspond-
ing human values, respectively (Tables 1 and 2).
The dose of mianserin employed in our subsequent
human study was determined by extrapolating the ratio
of rectal to oral exposure observed in the dog study and
considering this in the context of previous oral studies
in humans. The efficacy of 10–90 mg mianserin/day had
been previously reported in the context of delirium. An
open-label clinical trial on aged patients with delirium
demonstrated that 49/62 patients (85.5 %) were judged
responders; doses of ≤ 30 mg mianserin were also effective
in 85.7 % of these responders [8]. A separate open-label
study on aged patients showed an effect of mianserin on
delirium [7]. After an initial dose and titration period,
administration of 25–27 mg mianserin/day improved
delirium symptoms in 24/26 (92 %) of these patients.
Nakamura et al. also reported that an average dose of 25–
27 mg mianserin/day was effective in 85 % of 46 cases [9].
Therefore, we selected a rectal mianserin dose of 30 mg
for this study.
In humans, the plasma mianserin concentration also
increased slowly after rectal administration and while
the mean tmax was markedly delayed, the AUC0-24 was
80 % of that observed after oral administration. The dog
and human pharmacokinetic profiles of mianserin sup-
positories were therefore similar; both showed slower
and more sustained drug release, with a markedly de-
layed tmax, a higher concentration 24 h after administra-
tion, and comparable AUC0-24 values, as compared with
oral mianserin.
The sedative effect of mianserin, which reflects its an-
tagonist activities at histamine H1 receptors and alpha1-
adrenoceptors, was subjectively evaluated as a secondary
outcome following administration of mianserin supposi-
tories. In general, the lower Cmax observed following rec-
tal (as compared to oral) administration and the small
number of subjects meant that we did not observe sig-
nificant sedative effects in the present study. In one
Fig. 1 Pharmacokinetics of 30 mg mianserin after rectal and oral administration to beagle dogs. Data show the mean ± SD, n = 3
Table 1 Pharmacokinetics of mianserin after a single administration to beagle dogs
tmax (h) Cmax (ng/mL) AUC0-24 (h • ng/mL) AUC∞ (h • ng/mL)
Suppository (30 mg) 5.5 ± 4.3 1.3 ± 0.4 18.9 ± 1.9 29.5 ± 3.3
Oral tablets (3 × 10 mg) 0.5 8.6 ± 3.7 27.0 ± 8.6 23.8 ± 7.7
Mean ± SD, n = 3
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subject, sedation scores were higher 30 min after admin-
istration than at baseline, with drowsiness reaching a
maximum value (100 mm) 2 h after administration. This
subject had a mianserin level that was three-fold higher
than that of the other two subjects at this time-point;
this is likely to have contributed to this sedative effect.
Furthermore, this subject fainted 4 h and 8 h after ad-
ministration when his mianserin levels were 10 ng/mL
and 21.9 ng/mL, respectively; these levels were two-fold
higher than those of the other subjects and approached
50 % of the Cmax reported after oral administration of
30 mg mianserin (45.2 ng/mL; Tetramide® insert). No
rapid increase in the plasma mianserin level was ob-
served, suggesting that this did not cause the adverse
events. Nevertheless, attention needs to be paid to side
effects in order to ensure the safe use of mianserin
suppositories.
We found that plasma concentrations of mianserin
24 h after rectal administration were still high, and the
mianserin suppository AUC∞ was comparable to that
observed following oral administration, despite the lower
Cmax. Therefore, it is possible that the plasma level at
steady-state will be much higher than that after a single
Fig. 2 Pharmacokinetics of 30 mg mianserin after rectal administration
in healthy adult males. Closed squares represent the data from healthy
adult males receiving 30 mg mianserin by rectal administration.
Data show the mean ± SD, n = 3. The solid line represents the curve
fitted according to the 1-compartment model with first-order
absorption equation (1). In order to estimate ka and Vd, mianserin
pharmacokinetic data after rectal administration were fitted to
equation (1) by nonlinear least-squares regression analysis with a
fixed ke value. The estimated values of ka and Vd/F were 0.146 ±
0.052 1/h (mean ± SD, n = 3) and 1395 ± 497 L, respectively
Table 2 Pharmacokinetics of mianserin after a single administration to healthy male subjects
tmax (h) Cmax (ng/mL) AUC0-24 (h • ng/mL) AUC∞ (h • ng/mL)
Suppository (30 mg) 8a) 14.6 ± 6.3a) 266 ± 103a) 541.8 ± 189.4a)
Oral tablets (30 mg) 2.0 ± 0.1b) 40.7 ± 2.6b) 338.5c) 435.4 ± 35.3b)
a) The present study data, expressed as mean ± SD, n = 3
b) Data derived from the package insert of Tetramide® Tablets
c) Values estimated from the plasma concentration profile in the Tetramide® Tablet package insert
Fig. 3 Predicted pharmacokinetics after rectal administration of
mianserin by suppository. a 30 mg × 1, b 30 mg × 2, c 60 mg × 2
Nawata et al. Journal of Pharmaceutical Health Care and Sciences  (2016) 2:12 Page 6 of 7
administration. Furthermore, it is possible that a higher
dose or multiple dosing will be required in order to
achieve a sufficient plasma level to treat delirium. For
reference, we conducted an estimation of pharmacokinetic
parameters during multiple-dosing using a 1-compartment
model with first-order absorption equation. Once-daily ad-
ministration of 30-mg suppositories achieved a plasma
concentration of 20 ng/mL, which corresponded to the
level produced by oral dosing in healthy young adults (Tet-
ramide® insert) within 72 h of administration. Twice-daily
administration of 60 mg using suppositories achieved a
plasma concentration of 60–80 ng/mL, which corre-
sponded to the level observed after oral dosing of patients
with delirium [9, 17] within 36 h of administration. Further
studies are needed to characterize the rectal dose-plasma
concentration relationship, plasma concentrations beyond
24 h after administration, and steady-state pharmacokinet-
ics after multiple doses.
Conclusions
In conclusion, the results of the current study indicate
that rectal administration of a suppository prepared
using mianserin hydrochloride tablets and Witepsol H-
15 results in slow systemic mianserin exposure and a
lower Cmax as compared with oral tablet administration.
Our findings provide a preliminary indication that rectal
suppository administration could provide a comparable
exposure to mianserin and might offer an alternative
route in patients in which oral administration is not pos-
sible. Future studies should aim to clarify the relation-
ship between the rectal mianserin dose and the blood
concentration in order to use this route effectively and
safely.
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